IMPLANET Secures FDA Clearance for 3D-Printed Swingo Cervical Spine Cage
Key Insights
IMPLANET (search) received FDA 510(k) clearance for its Swingo (search) anterior cervical cage, featuring 3D-printed titanium construction and multiple implant sizes designed for vertebral anatomy.
The device was developed by an international surgeon panel established in 2024 and includes next-generation instrumentation aimed at enhancing patient safety while reducing surgical time.
Combined with the company's JSS (search) posterior fusion system, the clearance enables IMPLANET (search) to offer comprehensive spinal fusion solutions in the U.S. spine surgery market valued at $1.35 billion.
IMPLANET (search), a French medical technology company specializing in orthopedic implants, announced it has received FDA 510(k) clearance for its Swingo (search) anterior cervical cage, marking a significant expansion of the company's spinal fusion portfolio in the United States market.
Advanced 3D-Printed Design
The Swingo (search) cage range features titanium implants manufactured using 3D printing technology, offering a broad portfolio of implant sizes with design specifically tailored to vertebral anatomy. This design approach ensures improved control of interbody fusion and versatility across all types of spinal procedures, regardless of the surgical approach chosen by surgeons.
Developed through collaboration with a dedicated development group established in 2024 comprising a panel of international surgeons, the device represents IMPLANET (search)'s commitment to surgeon-driven innovation. The clearance includes a dedicated next-generation instrumentation range designed to enhance patient safety while reducing surgical time.
Strategic Market Positioning
Ludovic Lastennet, CEO of IMPLANET (search), emphasized the strategic importance of this clearance: "This new clearance marks an important milestone for IMPLANET. In the short term, combined with JSS (search) (posterior fusion system), it will enable us to offer a comprehensive range of implants dedicated to spinal fusion in the United States, our priority market."
The approval positions IMPLANET (search) to compete more effectively in the U.S. spine surgery segment, which the company estimates at $1.35 billion. The expanded product portfolio creates potential synergies that support the company's strategy to strengthen its U.S. presence, representing what Lastennet described as "another structural step in our development plan."
Global Market Access
Beyond the immediate U.S. market opportunity, the FDA clearance provides IMPLANET (search) with enhanced global commercialization capabilities. The company can now market the Swingo (search) range alongside its existing portfolio through distributors in countries that recognize U.S. FDA regulations, while awaiting CE marking approval for the European market.
Company Background
IMPLANET (search) operates as a medical technology company manufacturing high-end orthopedic implants and distributing advanced medical equipment. The company's business centers around innovative spinal pathology solutions, including the JAZZ (search) system and Jazz Spinal System hybrid fixation system, developed in partnership with Shanghai Sanyou Medical Co., Ltd (search).
The company employs 46 people and generated consolidated revenue of €12.5 million in 2025. Based near Bordeaux, France, IMPLANET (search) has maintained a U.S. subsidiary in Boston since 2013 and trades on the Euronext Growth market in Paris.